

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Cisco Webex, (408)418-9388
Meeting ID: 2480 672 2541
Password: m2ACcUtTc65

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aasejo@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK: <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MUST SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE.

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. IT WOULD BE APPRECIATED IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING. IF THAT IS NOT POSSIBLE, EVERY EFFORT WILL BE MADE TO ATTEMPT TO REVIEW E-COMMENTS DURING THE COURSE OF THE MEETING. TOWARDS THIS END, THE CHAIR OF THE COMMITTEE WILL ENDEAVOR TO TAKE A BRIEF PAUSE BEFORE ACTION IS TAKEN ON ANY AGENDA ITEM TO ALLOW THE COMMITTEE CLERK TO REVIEW E-COMMENTS, AND SHARE ANY E-COMMENTS RECEIVED DURING THE MEETING.

AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <ul style="list-style-type: none"> Agenda Overview 	2 min	-
II)	Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> Welcome Dr. Carey Medical-RX Update COVID-19 Update 2021 DHCS Audit Update CalAIM ECM/ILOS/MOT Update 	15 min	-
III)	Pharmacy Utilization Reports (Quarter 2) <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i> <ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs 	2 min	-

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
Peak Flow Meters	<ul style="list-style-type: none"> Add six OTC peak flow meters to formulary for IHSS
Glaucoma	<ul style="list-style-type: none"> No changes
Influenza antivirals	<ul style="list-style-type: none"> No changes
Physician Administered Drug Guidelines	Changes
Specialty Biological Agents for Crohn's Disease	<ul style="list-style-type: none"> Remove: "members who require Humira 40 mg SC weekly, documentation must be submitted indicating that the member was compliant (consistent with pharmacy claims) with receiving at least 16 weeks of continuous Humira therapy every other week prior to the request for weekly dosing of Humira."
Specialty Biological Agents for Rheumatoid Arthritis	<ul style="list-style-type: none"> Remove: "member was compliant (consistent with pharmacy claims) with receiving at least 16 weeks of continuous Humira therapy every other week prior to the request for weekly dosing of Humira."
Injectable/Infusible Agents for Osteoporosis and Paget's Disease	<ul style="list-style-type: none"> Correct spelling of "teriparatide"
Adakveo	<ul style="list-style-type: none"> No changes
Medication Request Guidelines	Changes
Specialty Biological Agents for Crohn's Disease	<ul style="list-style-type: none"> Remove: "members who require Humira 40 mg SC weekly, documentation must be submitted indicating that the member was compliant (consistent with pharmacy claims) with receiving at least 16 weeks of continuous Humira therapy every other week prior to the request for weekly dosing of Humira."
Specialty Biological Agents for Rheumatoid Arthritis	<ul style="list-style-type: none"> Remove: "member was compliant (consistent with pharmacy claims) with receiving at least 16 weeks of continuous Humira therapy every other week prior to the request for weekly dosing of Humira."
Calcitonin Gene-Related Peptide (CGRP) Antagonists for Headache Prevention	<ul style="list-style-type: none"> Update policy to include Nurtec ODT Minor wording changes in the criteria and criteria statement
Acute Migraine Treatments	<ul style="list-style-type: none"> Update policy to direct requests for Nurtec ODT to the CGRPs for headache prevention policy Minor wording changes in the criteria and criteria statement.

10
min

EV
(on
each
topic)

Oriahnn	<ul style="list-style-type: none"> Add new agent Myfembree and change policy name to Gonadotropin Releasing Hormone Antagonist Combination Products
Injectable/Infusible Bone-Modifying Agents for Oncology Indications	<ul style="list-style-type: none"> Add renal insufficiency as reason to use Xgeva Specify brand/generic names for clarity
Antiemetics	<ul style="list-style-type: none"> Add Emend powder packet to NF medications IHSS: Change palonosetron (Aloxi) IV solution 0.25mg/2ml vial, 0.25mg/5ml syringe from NF to F-PA
Topical Acne Agents	<ul style="list-style-type: none"> Remove section regarding Benzamycin
Adenosine Triphosphate-Citrate Lyase (ACL) inhibitors	<ul style="list-style-type: none"> Add “any newly marketed agent” Minor wording changes to reauthorization statement
Non-Formulary and PA Required Medications without Drug-Specific Criteria	<ul style="list-style-type: none"> Correct spelling of “label”
Oral and Injectable Oncology Medications	<ul style="list-style-type: none"> Change brand / generic status of Zytiga 500mg tablets
Orilissa (elagolix)	<ul style="list-style-type: none"> Minor wording adjustments to criteria and criteria statement
Injectable/Infusible Agents for Osteoporosis and Paget’s Disease	<ul style="list-style-type: none"> Minor wording changes to criteria statement Correct spelling of “teriparatide”
Dronabinol	<ul style="list-style-type: none"> Minor wording changes to criteria statement
Desvenlafaxine succinate (Pristiq)	<ul style="list-style-type: none"> Minor wording changes to criteria statement
Corticosteroids for Ulcerative Colitis and Crohn’s disease	<ul style="list-style-type: none"> Add in generic forms and the word “and”
Ophthalmic Anti-Inflammatory Agents	<ul style="list-style-type: none"> Add Bromsite and change formulary status from NF to F-PA for IHSS Add in strengths of medications and note that Durezol has a quantity limit
Moxifloxacin Oral Tablet	<ul style="list-style-type: none"> Minor wording changes to criteria statement
Malaria prophylaxis and treatment agents	<ul style="list-style-type: none"> Change policy name to Atovaquone-proguanil (Malarone)
Cartilaginous Repair Agents	<ul style="list-style-type: none"> Update name of Genvisc 850
Safety Edit Exception	<ul style="list-style-type: none"> No changes
Quantity Limit Exception	<ul style="list-style-type: none"> No changes
Nuedexta (dextromethorphan/quinidine)	<ul style="list-style-type: none"> No changes
Memantine ER (Namenda XR)	<ul style="list-style-type: none"> No changes
Vancomycin	<ul style="list-style-type: none"> No changes
Diclofenac sodium (Solaraze) 3% gel	<ul style="list-style-type: none"> No changes
Multaq (dronedarone)	<ul style="list-style-type: none"> No changes
Inhaler Assistant Devices	<ul style="list-style-type: none"> No changes
Mesalamine	<ul style="list-style-type: none"> No changes
Rifabutin (Mycobutin)	<ul style="list-style-type: none"> No changes
Spravato (esketamine) Intranasal	<ul style="list-style-type: none"> No changes

Santyl Ointment	• No changes
Physician Administered Medication (PAD)/ Medical Benefit Guidelines	• No changes
Off-label uses	• No changes
Interim Formulary changes	
See p. in packet	
Pharmacy Policy & Procedure	
No updates	
90 Day Maintenance List	
No updates	
ED Oversight	
No updates	
P&T Meeting Minutes	
P&T Meeting Minutes Q2 June 15, 2021	

ADJOURN TO CLOSED SESSION (Pursuant to California Government Code Title 5, §54954.5(h))

Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: 9/21/2021 (formulary changes only; no trade secrets will be disclosed).

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- **New MRG:** Topical Antibiotics
- **New PAD criteria & monograph:** Aduhelm

VI) PAD Revisions

Natalee Felten, PharmD, Pharmacist, PerformRx

- Erythropoiesis-Stimulating Agents
- White Blood Cell Stimulators
- Iron-containing products
- Exondys 51

VII) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

45
min

V

1. IBS-C D CIC and opioid induced constipation
2. Intranasal steroid
3. Chelating agents

VIII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

1. Opioid Dependency Agents
2. Erythropoiesis-Stimulating Agents
3. White Blood Cell Stimulators
4. Injectable Atypical Antipsychotic Medications
5. Anti-Obesity Medications
6. Pediculicides

IX) Medication Request Guidelines continued

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

7. Raloxifene (Evista) – retire
8. Rifamycin Antibiotics
9. Botulinum Toxins A&B
10. Sedative Hypnotics
11. Makena
12. Medications for the treatment of Multi-Drug Resistant Tuberculosis
13. Tetracycline Antibiotics
14. Diabetes Medications and Diabetes Medications used for Heart Failure or Chronic Kidney Disease

X) Summary of Closed Session

Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance

RECONVENE IN OPEN SESSION

ITEM	DESCRIPTION	TIME	VOTE
XI)	Informational Updates on New Developments in Pharmacy <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>	2 min	-
	<ul style="list-style-type: none"> • New Product Review 		
XII)	Old Business	0 min	
	<ul style="list-style-type: none"> • None 		
XIII)	Public Comment	0 min	-
XIV)	Adjournment		
	<ul style="list-style-type: none"> • P&T Committee Member Forms 		

ACTION / FOLLOW-UP ITEMS

ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
NEXT MEETING	2022 P&T MEETINGS
December 21 st , 2021	March 15 th , 2022
	June 21 st , 2022

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.